San Diego, Calif. – October 28, 2025 — We are here to announce our participation in the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
Please visit our exhibition at Booth #640. Where we will be highlighting the breakthrough vTIME platform and launching a new Immuno-Oncology PD-1 Combination Therapy Testing Campaign designed to accelerate preclinical evaluation using vascularized human tumor models.
We will also present Poster #1271, titled “An IND-Enabling, High-Fidelity 3D Vascularized TIME Model for IO Drug Evaluation,” showcasing how its organoid-based platform bridges the gap between preclinical and clinical efficacy. Additionally, Qureator’s collaboration with SillaJen will be featured in Poster #621, underscoring the companies’ joint success in achieving the world’s first FDA IND approval based solely on human organoid efficacy data.